3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Ovarian Neoplasms
4
Breast Neoplasms
3
Multiple Myeloma
2
Fallopian Tube Neoplasms
2
Stomach Neoplasms
1
Sarcoma
1
Platinum-resistant Recurrent Ovarian Cancer
1
Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
1
Ovarian Cancer Recurrent
1
Lymphoma, Follicular
1
Lymphoma
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Advanced Ovarian Cancer
1
Interventions
Rituximab
130
Cyclophosphamide
113
Peripheral Blood Stem Cell Transplantation
59
fludarabine phosphate
55
Etoposide
47
Mycophenolic Acid
44
Radiotherapy
41
Filgrastim
41
Tacrolimus
40
Whole-Body Irradiation
36
Busulfan
34
Melphalan
33
Cyclosporine
30
Cytarabine
29
Methotrexate
28
sargramostim
27
Vincristine
27
Antilymphocyte Serum
27
Prednisone
26
Lenalidomide
23
obinutuzumab
22
Doxorubicin
22
Carmustine
21
Bortezomib
20
Methylprednisolone
19
fludarabine
17
Dexamethasone
17
Bendamustine Hydrochloride
17
ibritumomab tiuxetan
15
Cord Blood Stem Cell Transplantation
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Lymphoma, Follicular
×
1-dodecylpyridoxal
×
Clear all
NCT06425302
2026-01-08
GOLSEEK-2
Celgene
Phase 2
Active not recruiting
90 enrolled